Bringing the latest clinical research trials to the Scottsdale area.
Removing the health care disparities in our communities by bringing treatment options to a growing and diverse population.
We're always looking for participants to help participate in our clinical research trials.
The Toronto Memory Program is Canada's most experienced site for drug treatment trials in Alzheimer's disease and related conditions.Learn More
To refer patients for consultation to our Memory Clinic, click Learn More.Learn More
Partner with a leading clinical trials site with a strong track record of success and a commitment to excellence.Learn More
Please support the Toronto Memory Program Fund for Education to provide education to patients, caregivers, and the community.Learn More
Dr. Sharon Cohen, the Director of the Toronto Memory Program, is a Canadian-trained Neurologist specializing in behaviour and cognition, as well as an internationally recognized expert in this field. Dr. Cohen is an assistant professor in the University of Toronto's Division of Neurology and Graduate Department of Speech Language Pathology.
Clinical research is the scientifically accepted method for determining whether medications or devices are safe, tolerable, and effective to treat a specific condition. Clinical trials in humans occur only after evaluation of a treatment in the laboratory and in animal studies.
Through clinical trials, doctors find new and better ways to prevent, detect, diagnose, control, treat and cure illnesses. Clinical trials are dependent on the participation of volunteers, who join with scientists, to make advances in medicine possible.
We are committed to providing the highest quality of clinical research in Canada for the following conditions and more:
-Mild Cognitive Impairment
-Lewy Body Dementia
-Alzheimer's Disease Prevention
-MigraineView Current Studies Contact Us
With over 700,000 Canadians living with Alzheimer’s disease, finding successful new treatments is more crucial than ever. At Toronto Memory Program, we specialize in Alzheimer’s disease prevention, diagnosis and the use of currently approved treatments. However, we need patients, and the public, to partner with us by participating in clinical trials to move forward potential new treatments If you are interested in learning more about our current enrolling clinical trials, visit our Current Studies page for more information.View Current Studies Contact Us
Mild Cognitive Impairment (MCI) is a term used to describe a mild degree of cognitive decline along with a preservation of independent function. Identifying the cause of MCI early is important to preserve cognition and optimize treatment. MCI is a risk factor for progression to dementia. Learn more about our MCI & Early Alzheimer’s disease enrolling trials by clicking the Current Studies tab.
View Current Studies Contact Us
Parkinson’s is a chronic degenerative neurological disease caused by a loss of dopamine producing cells in the brain. Currently, more than 100,000 Canadians are living with Parkinson’s disease and with no cure. That's why we need your help!
Check out information about our Movement Disorder Clinic and our Current Studies page to learn more about how we are doing our part to combat Parkinson's disease.View Current Studies Contact Us
Lewy Body dementia is a common form of dementia. In addition to cognitive symptoms other features such as fluctuations, visual hallucinations, Parkinson-like symptoms, and acting out out dreams may be prominent. If you are experiencing these symptoms, or have been diagnosed with Lewy Body Dementia, click on our current studies tab and learn more about our clinical trials.View Current Studies Contact Us
Our best hope for managing Alzheimer’s disease is to either prevent it from happening or delay the onset of symptoms. Clinical trials at this stage try to disrupt the root causes and keep healthy people healthy. If you are interested in learning more about our current enrolling prevention trials, visit our Current Studies page for more informationView Current Studies Contact Us
New and better treatments for migraine management are needed. Many individuals continue to suffer from often debilitating headaches that significantly affect their quality of life. To learn more about Migraine treatment trials click on the Current Studies icon below.View Current Studies Contact Us
Neurologist Dr. Sharon Cohen joined Matt Gurney on CanadaTalks SiriusXM for a discussion of the
Dr. Sharon Cohen, Medical Director and Principal Investigator at Toronto Memory Program discusses the exciting
This video describes the medication under investigation in the PTI-125-004 Alzheimer's disease clinical trial
Steve McNeil @1926Skate skates every year on his mother's birthday for 19-hours and 26-minutes to
Gratitude to CTV NewsChannel's Marcia MacMillan for inviting #Alzheimer's fundraiser and marathon ice-skater Steve McNeil
Thanks to CNBC's Meg Tirrell for including comments from Toronto Memory Program's Dr. Sharon Cohen
Toronto Memory Program's new RetiSpec scan study was featured by CTV's Pauline Chan on August
Dr. Sharon Cohen, Medical Director and Principal Investigator at Toronto Memory Program, discusses the exciting news that FDA has approved the use of aducanumab.
The first new treatment for Alzheimer’s disease in 20 years and the very first disease-modifying drug proven to slow AD progression.
1 Valleybrook Drive
Toronto, ON M3B 2S7